Safety of medicines used in ADHD: a review of published prospective clinical trials.
|
An extensive bibliographic search using a variety of databases to evaluate prospective studies which examined the incidence of drug adverse events (AEs) in children with ADHD, indicates that treatment-related AEs range from 58%-78% with discontinuation of the drug/s occurring in 8%-25% of children. Few studies however evaluate the long-term safety of drugs for ADHD.
Archives of Disease in Childhood
|
Propranolol for severe infantile hemangiomas (IH).
|
Infantile hemangiomas are benign vascular neoplasms that increase in size early, followed frequently by spontaneous resolution. 60% of them are found on the head and neck, and are usually focal, well circumscribed and <5cm in size. A small percent of complicated infantile hemangiomas need early, safe and effective systemic treatment.
Propranolol is sympatholytic non-selective beta blocker which has been used off label since 2008 for IH patients. Recently the FDA has approved an oral formulation for those patients requiring systemic therapy.
A retrospective review of 207 pediatric patients with complicated IH treated with systemic propranolol indicates that this therapy is highly effective and "nearly always safe" (no side-effects produced requiring discontinuation of therapy).
Acta Paediatrica
|
Updates in Pediatrics is brought to you by:
|
|
|
Download, print and pin this information on your office wall.
-This is a "Must Have" (Ed.)
|